Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

Katherine Luzuriaga, Yvonne Bryson, George McSherry, James Robinson, Barbara Stechenberg, Gwendolyn Scott, Michael Lamson, Susannah Cort, John L. Sullivan

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Phase 1 trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses ≤240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to <50% of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.

Original languageEnglish (US)
Pages (from-to)713-721
Number of pages9
JournalJournal of Infectious Diseases
Volume174
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Nevirapine
HIV-1
Pharmacokinetics
Safety
Reverse Transcriptase Inhibitors
Exanthema
Antiviral Agents
Viruses
Antigens
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Luzuriaga, Katherine ; Bryson, Yvonne ; McSherry, George ; Robinson, James ; Stechenberg, Barbara ; Scott, Gwendolyn ; Lamson, Michael ; Cort, Susannah ; Sullivan, John L. / Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. In: Journal of Infectious Diseases. 1996 ; Vol. 174, No. 4. pp. 713-721.
@article{0e4b96338fe54a1b8c8f06fe0c9a298b,
title = "Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children",
abstract = "Phase 1 trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses ≤240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to <50{\%} of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.",
author = "Katherine Luzuriaga and Yvonne Bryson and George McSherry and James Robinson and Barbara Stechenberg and Gwendolyn Scott and Michael Lamson and Susannah Cort and Sullivan, {John L.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1093/infdis/174.4.713",
language = "English (US)",
volume = "174",
pages = "713--721",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

Luzuriaga, K, Bryson, Y, McSherry, G, Robinson, J, Stechenberg, B, Scott, G, Lamson, M, Cort, S & Sullivan, JL 1996, 'Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children', Journal of Infectious Diseases, vol. 174, no. 4, pp. 713-721. https://doi.org/10.1093/infdis/174.4.713

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. / Luzuriaga, Katherine; Bryson, Yvonne; McSherry, George; Robinson, James; Stechenberg, Barbara; Scott, Gwendolyn; Lamson, Michael; Cort, Susannah; Sullivan, John L.

In: Journal of Infectious Diseases, Vol. 174, No. 4, 01.01.1996, p. 713-721.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

AU - Luzuriaga, Katherine

AU - Bryson, Yvonne

AU - McSherry, George

AU - Robinson, James

AU - Stechenberg, Barbara

AU - Scott, Gwendolyn

AU - Lamson, Michael

AU - Cort, Susannah

AU - Sullivan, John L.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Phase 1 trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses ≤240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to <50% of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.

AB - Phase 1 trials were conducted in human immunodeficiency virus type 1 (HIV-1)-infected children to examine the pharmacokinetics, safety, and antiretroviral activity of nevirapine, a nonnucleoside HIV-1 reverse transcriptase inhibitor. Nevirapine was rapidly absorbed, but the time to peak plasma concentrations increased with higher doses. Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children. Rash, which occurred in 1 of the 21 study participants, was the single toxicity regarded as nevirapine-related. At doses ≤240 mg/m2/day, 5 of 10 children experienced durable suppression of plasma p24 antigen to <50% of baseline values through 8 weeks of nevirapine monotherapy. Viruses resistant to nevirapine were isolated from all children during therapy, but their isolation did not always predict loss of antiviral activity. The evaluation of nevirapine in combination therapy trials is underway in children.

UR - http://www.scopus.com/inward/record.url?scp=0029845343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029845343&partnerID=8YFLogxK

U2 - 10.1093/infdis/174.4.713

DO - 10.1093/infdis/174.4.713

M3 - Article

C2 - 8843207

AN - SCOPUS:0029845343

VL - 174

SP - 713

EP - 721

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -